ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Warning against untested stem cell use by dodgers – TopNews United States

TopNews United StatesThis doubtful treatment is not priced reasonably and can cost anything from €100,000, and above says Dr Massimo Dominici, president elect of the International Society for Cellular Therapy. Dr Dominici along with other experts doing the research on stem …Scientists Warn to Avoid Treatment by Fake & Untested Stem CellFrench Tribune all 2 … Continue reading

2013-09-10 Michael Zand NEWS

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial – Daily Markets (press release)

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialDaily Markets (press release)ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS

Migration capacity of human umbilical cord mesenchymal stem cells towards … – Science Codex

Migration capacity of human umbilical cord mesenchymal stem cells towards …Science CodexGlioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor … …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS

Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial – NASDAQ

Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell TrialNASDAQ(RTTNews.com) – Neuralstem Inc. ( CUR ) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory …First Patient Treated In … Continue reading

2013-09-10 Michael Zand NEWS

Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial – RTT News

Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell TrialRTT NewsNeuralstem Inc. (CUR: Quote) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory University … and more …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS

UTHSC Researcher Reveals Cell Transplants As Possible Novel Schizophrenia … – BioNews Texas

BioNews TexasDaniel Lodge, Ph.D., senior author and assistant professor of pharmacology in the School of Medicine, believes that these interneurons can be replaced with stem cells and that should restore lost function. In the current study, Lodge and colleagues … and more …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS

Scientists Warn to Avoid Treatment by Fake & Untested Stem Cell – French Tribune

Scientists Warn to Avoid Treatment by Fake & Untested Stem CellFrench TribuneMedical experts are concerned that people are buying untested stem cells for medical treatment, which could prove to be very dangerous. Most of the people buying these phony stem cells are suffering from incurable degenerative diseases, who are ready … …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial – Wall Street Journal

First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialWall Street JournalROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … …read more   &nbs… Continue reading

2013-09-10 Michael Zand NEWS
  • 1
  • …
  • 3,508
  • 3,509
  • 3,510
  • 3,511
  • 3,512
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.